Cargando…

The clinical value and cost-effectiveness of treatments for patients with coronary artery disease

BACKGROUND: The clinical value and cost-effectiveness of invasive treatments for patients with coronary artery disease is unclear. Invasive treatments such as coronary artery bypass grafting and percutaneous coronary intervention are frequently used as a starting treatment, yet they are much more co...

Descripción completa

Detalles Bibliográficos
Autores principales: Weiting, Huang, Yaoxian, Alwin Zhang, Keong, Yeo Khung, Lam, Shao Wei, How, Lau Yee, Sahlén, Anders Olof, Pourghaderi, Ahmadreza, Che, Matthew, Terrance, Chua Siang Jin, Graves, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644580/
https://www.ncbi.nlm.nih.gov/pubmed/36348165
http://dx.doi.org/10.1186/s13561-022-00401-y
_version_ 1784826772945108992
author Weiting, Huang
Yaoxian, Alwin Zhang
Keong, Yeo Khung
Lam, Shao Wei
How, Lau Yee
Sahlén, Anders Olof
Pourghaderi, Ahmadreza
Che, Matthew
Terrance, Chua Siang Jin
Graves, Nicholas
author_facet Weiting, Huang
Yaoxian, Alwin Zhang
Keong, Yeo Khung
Lam, Shao Wei
How, Lau Yee
Sahlén, Anders Olof
Pourghaderi, Ahmadreza
Che, Matthew
Terrance, Chua Siang Jin
Graves, Nicholas
author_sort Weiting, Huang
collection PubMed
description BACKGROUND: The clinical value and cost-effectiveness of invasive treatments for patients with coronary artery disease is unclear. Invasive treatments such as coronary artery bypass grafting and percutaneous coronary intervention are frequently used as a starting treatment, yet they are much more costly than optimal medical therapy. While patients may transition into other treatments over time, the choices of starting treatments are likely important determinants of costs and health outcomes. The aim is to predict by how much costs and health outcomes will change from a decision to use different starting treatments for patients with coronary artery disease in an Asian setting. METHODS: A cost-effectiveness study using a Markov model informed by data from Singapore General Hospital was done. All patients with initial presentations of stable coronary disease and no acute coronary syndromes who received medical treatments and interventional therapies were included. We compare existing practice, where the starting treatment can be medical therapy or stent percutaneous coronary interventions or coronary artery bypass grafting, with alternate starting treatment strategies. RESULTS: When compared to ‘existing practice’ a policy of starting 14% of patients with coronary artery bypass grafting and 86% with optimal medical therapy showed savings of $1,743 per patient and 0.23 additional quality adjusted life years. A change to policy nationwide would save $10 million and generate 1,380 quality adjusted life years. CONCLUSIONS: Increasing coronary artery bypass grafting and use of medical therapy in the setting of coronary artery disease is likely to saves costs and improve health outcomes. A definitive study to address the question we investigate would be very difficult to undertake and so using existing data to model the expected outcomes is a useful tool. There are likely to be large and complex barriers to the implementation of any policy change based on the findings of this study.
format Online
Article
Text
id pubmed-9644580
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96445802022-11-15 The clinical value and cost-effectiveness of treatments for patients with coronary artery disease Weiting, Huang Yaoxian, Alwin Zhang Keong, Yeo Khung Lam, Shao Wei How, Lau Yee Sahlén, Anders Olof Pourghaderi, Ahmadreza Che, Matthew Terrance, Chua Siang Jin Graves, Nicholas Health Econ Rev Research BACKGROUND: The clinical value and cost-effectiveness of invasive treatments for patients with coronary artery disease is unclear. Invasive treatments such as coronary artery bypass grafting and percutaneous coronary intervention are frequently used as a starting treatment, yet they are much more costly than optimal medical therapy. While patients may transition into other treatments over time, the choices of starting treatments are likely important determinants of costs and health outcomes. The aim is to predict by how much costs and health outcomes will change from a decision to use different starting treatments for patients with coronary artery disease in an Asian setting. METHODS: A cost-effectiveness study using a Markov model informed by data from Singapore General Hospital was done. All patients with initial presentations of stable coronary disease and no acute coronary syndromes who received medical treatments and interventional therapies were included. We compare existing practice, where the starting treatment can be medical therapy or stent percutaneous coronary interventions or coronary artery bypass grafting, with alternate starting treatment strategies. RESULTS: When compared to ‘existing practice’ a policy of starting 14% of patients with coronary artery bypass grafting and 86% with optimal medical therapy showed savings of $1,743 per patient and 0.23 additional quality adjusted life years. A change to policy nationwide would save $10 million and generate 1,380 quality adjusted life years. CONCLUSIONS: Increasing coronary artery bypass grafting and use of medical therapy in the setting of coronary artery disease is likely to saves costs and improve health outcomes. A definitive study to address the question we investigate would be very difficult to undertake and so using existing data to model the expected outcomes is a useful tool. There are likely to be large and complex barriers to the implementation of any policy change based on the findings of this study. Springer Berlin Heidelberg 2022-11-08 /pmc/articles/PMC9644580/ /pubmed/36348165 http://dx.doi.org/10.1186/s13561-022-00401-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Weiting, Huang
Yaoxian, Alwin Zhang
Keong, Yeo Khung
Lam, Shao Wei
How, Lau Yee
Sahlén, Anders Olof
Pourghaderi, Ahmadreza
Che, Matthew
Terrance, Chua Siang Jin
Graves, Nicholas
The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title_full The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title_fullStr The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title_full_unstemmed The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title_short The clinical value and cost-effectiveness of treatments for patients with coronary artery disease
title_sort clinical value and cost-effectiveness of treatments for patients with coronary artery disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9644580/
https://www.ncbi.nlm.nih.gov/pubmed/36348165
http://dx.doi.org/10.1186/s13561-022-00401-y
work_keys_str_mv AT weitinghuang theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT yaoxianalwinzhang theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT keongyeokhung theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT lamshaowei theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT howlauyee theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT sahlenandersolof theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT pourghaderiahmadreza theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT chematthew theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT terrancechuasiangjin theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT gravesnicholas theclinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT weitinghuang clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT yaoxianalwinzhang clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT keongyeokhung clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT lamshaowei clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT howlauyee clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT sahlenandersolof clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT pourghaderiahmadreza clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT chematthew clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT terrancechuasiangjin clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease
AT gravesnicholas clinicalvalueandcosteffectivenessoftreatmentsforpatientswithcoronaryarterydisease